Month: May 2024

LATHAM, N.Y., May 30, 2024 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, invites investors and the general public to listen to a webcast of its annual meeting of stockholders on Wednesday, June 5, 2024, at 10:00 a.m. Eastern Time. The live webcast can be accessed through the Internet at www.virtualshareholdermeeting.com/PLUG2024. A general corporate overview and question and answer session is expected to follow the business portion of the annual meeting. The webcast can also be accessed directly from the Plug homepage (www.plugpower.com). A playback of the webcast will be available at www.plugpower.com for a period of time following the meeting. Stockholders of record will be able to submit questions on the day of the meeting in writing through...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, May 30, 2024 (GLOBE NEWSWIRE) — FRNT Financial Inc. (TSXV: FRNT) (OTCQB:FRFLF) (FSE:XZ3) (the “Company” or “FRNT”) is pleased to provide a business update as macro and cryptocurrency-market conditions improve. The Company is seeing a significant uptick in business pipeline beyond what has been seen historically, though experiencing volatility in the timing of revenue realization. While such volatility is to be expected as the industry emerges from aggressive bear-market conditions, the Company believes the revenue-generation potential of the business has re-rated and that recurring, more predictable quarterly figures are on the horizon. Advisory & Consulting FRNT Financial has entered into a number of engagements, advising...

CLEVELAND, May 30, 2024 (GLOBE NEWSWIRE) — Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that its direct subsidiary has successfully closed a new senior secured Term Loan B facility in an aggregate principal amount of $1.51 billion (the “TLB”) as well as an issuance of senior secured notes in an aggregate principal amount of $750.0 million (the “Notes”) (collectively, the “Financings”), both of which mature in 2031. The Company used the net proceeds from the Financings, along with cash on hand, to refinance its existing $1.76 billion Term Loan B and $496.3 million Term Loan B facilities. “We are pleased to announce the successful refinancing...

CALGARY, Alberta, May 30, 2024 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company“) (TSX: PRQ) is pleased to announce that its shareholders approved all resolutions at its annual general meeting of shareholders held May 29, 2024 (the “Meeting“). The resolutions approved at the Meeting were as follows: The resolution to fix the number of directors of the Company to be elected at the Meeting at five (5) directors was approved. The resolution to appoint the five (5) nominees as directors of the Company to serve until the next annual meeting of shareholders of the Company, was passed by way of ballot and the directors received the following votes:Nominee   Outcome of Vote   Votes For   % For   Votes Withheld   % WithheldDonald Gray   Elected   93,085,491   97.72%   2,169,375   2.28%                     Donald...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1 QALSODY is Biogen’s third rare disease therapy to be approved in the EU, demonstrating the company’s commitment to addressing diseases with a high unmet need With QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the fieldCAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for QALSODY® (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene...